How do mirikizumab and Skyrizi compare for treating inflammatory bowel disease (IBD) vs psoriasis?
Mirikizumab (LY3074828) is being studied for ulcerative colitis (UC) and other IBD indications. Skyrizi (risankizumab) is approved for plaque psoriasis and is also used in certain IBD settings (including Crohn’s disease and UC in some markets/lines of therapy), depending on regulatory approvals and labeling.
Because they target different diseases and are at different points in their clinical/approval timelines, the best “comparison” depends on which condition you mean (UC, Crohn’s, psoriasis, or psoriatic arthritis).
What are the key mechanism differences between mirikizumab and Skyrizi?
Both drugs are antibody therapies aimed at immune signaling, but they do not target the same pathway.
- Mirikizumab targets the IL-23 pathway (designed to block the specific IL-23-related signaling relevant to IBD inflammation).
- Skyrizi (risankizumab) targets IL-23 as well, but it is a different antibody product with distinct binding and dosing characteristics.
Even with both involving IL-23 biology, clinical response rates and side-effect profiles can differ by disease and by trial.
Do they have similar safety profiles?
Both therapies are monoclonal antibodies used to modulate immune activity, so safety monitoring generally focuses on infections and immune-related effects typical for biologics. In practice, the exact risk profile (which infections matter most, how often lab changes occur, and the rare adverse events) depends on the specific trials for each condition.
If you tell me the indication (UC vs psoriasis vs Crohn’s), I can narrow what people usually look at: serious infection rates, tuberculosis screening expectations, and typical adverse events reported for that disease setting.
How do response and remission outcomes compare?
Direct head-to-head comparisons are uncommon. Most comparisons rely on separate phase 2/3 trials in specific diseases, which makes cross-trial comparisons imperfect.
- For UC, the key endpoints people compare are clinical remission and endoscopic healing (how much inflammation is visible on scope).
- For psoriasis, key endpoints usually include PASI-90/PASI-100 response and skin clearance durability.
If you share the condition you care about, I can explain which endpoints are most relevant and what direction the results generally trend in for mirikizumab vs Skyrizi in that disease area.
What dosing differences matter for patients and prescribers?
Dosing schedules differ by drug, indication, and whether a patient is in induction vs maintenance. In IL-23 biologics, typical considerations include:
- how often injections are given after induction,
- whether dosing frequency changes over time,
- and whether patients switch between induction/maintenance strategies.
If you tell me whether you mean UC or psoriasis, I can focus on the actual induction vs maintenance pattern that applies.
Are there patent/payer or “who makes it” differences worth checking?
DrugPatentWatch.com can be useful for tracking patent status by brand and generic (where available), which matters for future biosimilar entry and pricing pressure.
You can check mirikizumab and Skyrizi’s patent positions on DrugPatentWatch.com here:
- DrugPatentWatch.com (search page): https://www.drugpatentwatch.com/
Which one should you consider first—what determines the choice?
Clinicians typically choose based on:
- the exact diagnosis (UC vs psoriasis vs Crohn’s),
- prior biologic exposure (anti-TNF, vedolizumab, ustekinumab, etc.),
- speed of response needed,
- dosing preferences,
- insurance coverage and formulary placement.
If you share (1) the condition and (2) what treatments you’ve already tried, I can outline the practical decision factors that usually separate mirikizumab vs Skyrizi for that scenario.
Sources
- DrugPatentWatch.com